Winners & Losers: A Deep-Dive Into The EMA’s PRIME Scheme
Nine of the 70 medicines for unmet medical needs that have to date won a place on the European Medicines Agency’s PRIME scheme are now approved for sale in the EU, and two more approvals are expected soon. Meanwhile, most applications for a "priority medicine" designation are still missing the mark.
You may also be interested in...
Among the six new investigational products to make it onto the European Medicines Agency’s priority medicines scheme, five were gene therapies.
Health technology assessment body NICE has reversed its previous rejection of the use of Polivy in combination with rituximab and bendamustine for treating diffuse large B-cell lymphoma.
The US Food and Drug Administration is expediting the review for Biogen’s Alzheimer’s therapy aducanumab, setting up a likely November/December advisory committee consideration that in normal times would be the dominant topic for those who care about the agency.